Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulrodemstat (CC-90011) to Reverse Castration Resistance in mCRPC
NCT04628988Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pulrodemstat in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Celgene Corporation. Primary endpoint: Assessment of androgen receptor level. Started Jul 2021; status: completed.
02
Drugs
pulrodemstat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04628988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04628988.